EMGE
Emergent Health Corp. develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and products for reducing facial wrinkles. The company distributes its products through health food stores, pharmacies, and various other retail outlets throughout the United States and internationally. Emergent Health Corp. is based in King of Prussia, Pennsylvania. As of August 26, 2014, Emergent Health Corp was taken private.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2024 Q3 | -0.00 | $0 | -$56,470 |
| 2024 Q2 | 0.00 | -$460,658 | $270,200 |
| 2024 Q1 | -0.00 | $460,658 | -$412,398 |
| 2023 Q4 | -0.00 | $334,216 | -$591,224 |
| 2023 Q3 | -0.00 | $560,449 | $53,476 |
| 2023 Q2 | -0.00 | $399,830 | -$352,417 |
| 2023 Q1 | -0.00 | $340,531 | -$329,637 |
| 2022 Q4 | -0.01 | $373,403 | -$498,113 |